High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial

Jenny E Han, Jennifer L Jones, Vin Tangpricha, Mona A Brown, Lou Ann S Brown, Li Hao, Gautam Hebbar, Moon Jeong Lee, Shuling Liu, Thomas R Ziegler, Greg S Martin, Jenny E Han, Jennifer L Jones, Vin Tangpricha, Mona A Brown, Lou Ann S Brown, Li Hao, Gautam Hebbar, Moon Jeong Lee, Shuling Liu, Thomas R Ziegler, Greg S Martin

Abstract

Background: There is a high prevalence of vitamin D deficiency in the critically ill patient population. Several intensive care unit studies have demonstrated an association between vitamin D deficiency [25-hydroxyvitamin D (25(OH)D) < 20 ng/mL] and increased hospital length of stay (LOS), readmission rate, sepsis and mortality.

Material and methods: Pilot, double blind randomized control trial conducted on mechanically ventilated adult ICU patients. Subjects were administered either placebo, 50,000 IU vitamin D3 or 100,000 IU vitamin D3 daily for 5 consecutive days enterally (total vitamin D3 dose = 250,000 IU or 500,000 IU, respectively). The primary outcome was plasma 25(OH)D concentration 7 days after oral administration of study drug. Secondary outcomes were plasma levels of the antimicrobial peptide cathelicidin (LL37), hospital LOS, SOFA score, duration of mechanical ventilation, hospital mortality, mortality at 12 weeks, and hospital acquired infection.

Results: A total of 31 subjects were enrolled with 13 (43%) being vitamin D deficient at entry (25(OH)D levels < 20 ng/mL). The 250,000 IU and 500,000 IU vitamin D3 regimens each resulted in a significant increase in mean plasma 25(OH)D concentrations from baseline to day 7; values rose to 45.7±19.6 ng/mL and 55.2 ± 14.4 ng/mL, respectively, compared to essentially no change in the placebo group (21±11.2 ng/mL), p<0.001. There was a significant decrease in hospital length of stay over time in the 250,000 IU and the 500,000 IU vitamin D3 group, compared to the placebo group (25 ± 14 and 18 ± 11 days compared to 36 ± 19 days, respectively; p=0.03). There was no statically significant change in plasma LL-37 concentrations or other clinical outcomes by group over time.

Conclusions: In this pilot study, high-dose vitamin D3 safely increased plasma 25(OH)D concentrations into the sufficient range and was associated with decreased hospital length of stay without altering other clinical outcomes.

Clinical trial registration: www.clinicaltrials.gov (NCT01372995).

Keywords: LL-37; antimicrobial peptides; critical care; lung failure; vitamin D.

Figures

Figure 1
Figure 1
CONSORT diagram of study subject enrollment, allocation and follow-up.
Figure 2
Figure 2
Plasma 25-hydroxyvitamin D concentrations by group over time. At study entry the mean plasma 25(OH)D was similar across all groups. By day 7, mean plasma 25(OH)D concentrations significantly increased in the vitamin D treatment groups compared to placebo, with sustained effects up to day 28. There was no statistical difference in the mean plasma 25(OH)D concentration between the 250,000 IU vitamin D3 group and the 500,000 IU vitamin D3 group.

References

    1. Jeng L., Yamshchikov A.V., Judd S.E., Blumberg H.M., Martin G.S., Ziegler T.R. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.
    1. Mata-Granados J.M., Vargas-Vasserot J., Ferreiro-Vera C., Luque de Castro M.D., Pavon R.G., Quesada Gomez J.M. Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol. 2010;121(1–2):452–455.
    1. Higgins D.M., Wischmeyer P.E., Queensland K.M., Sillau S.H., Sufit A.J., Heyland D.K. Relationship of vitamin D deficiency to clinical outcomes in critically ill patients. JPEN J Parenter Enteral Nutr. 2012;36(6):713–720.
    1. Nair P., Lee P., Reynolds C., Nguyen N.D., Myburgh J., Eisman J.A. Significant perturbation of vitamin D-parathyroid-calcium axis and adverse clinical outcomes in critically ill patients. Intensive Care Med. 2013;39(2):267–274.
    1. Braun A.B., Gibbons F.K., Litonjua A.A., Giovannucci E., Christopher K.B. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med. 2012;40(1):63–72.
    1. Quraishi S.A., Bittner E.A., Blum L., McCarthy C.M., Bhan I., Camargo C.A., Jr Prospective study of vitamin D status at initiation of care in critically ill surgical patients and risk of 90-day mortality. Crit Care Med. 2014;42(6):1365–1371.
    1. Barnett N., Zhao Z., Koyama T., Janz D.R., Wang C.Y., May A.K. Vitamin D deficiency and risk of acute lung injury in severe sepsis and severe trauma: a case-control study. Ann Intensive Care. 2014;4(1):5.
    1. Amrein K., Zajic P., Schnedl C., Waltensdorfer A., Fruhwald S., Holl A. Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care. 2014;18(2):R47.
    1. McNally J.D., Menon K., Chakraborty P., Fisher L., Williams K.A., Al-Dirbashi O.Y. The association of vitamin D status with pediatric critical illness. Pediatrics. 2012;130(3):429–436.
    1. Hebbar K.B., Wittkamp M., Alvarez J.A., McCracken C.E., Tangpricha V. Vitamin D deficiency in pediatric critical illness. J Clin Transl Endocrinol. 2014;1(4):170–175.
    1. Kempker J.A., Han J.E., Tangpricha V., Ziegler T.R., Martin G.S. Vitamin D and sepsis: an emerging relationship. Dermatoendocrinol. 2012;4(2):101–108.
    1. Kempker J.A., West K.G., Kempker R.R., Siwamogsatham O., Alvarez J.A., Tangpricha V. Vitamin D status and the risk for hospital-acquired infections in critically ill adults: a prospective cohort study. PLoS ONE. 2015;10(4) e0122136.
    1. Moromizato T., Litonjua A.A., Braun A.B., Gibbons F.K., Giovannucci E., Christopher K.B. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. Crit Care Med. 2014;42(1):97–107.
    1. Thickett D.R., Moromizato T., Litonjua A.A., Amrein K., Quraishi S.A., Lee-Sarwar K.A. Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: a retrospective cohort study. BMJ Open Respir Res. 2015;2(1):e000074.
    1. Dancer R.C., Parekh D., Lax S., D'Souza V., Zheng S., Bassford C.R. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS) Thorax. 2015;70(7):617–624.
    1. Barlow P.G., Beaumont P.E., Cosseau C., Mackellar A., Wilkinson T.S., Hancock R.E. The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am J Respir Cell Mol Biol. 2010;43(6):692–702.
    1. De Smet K., Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005;27(18):1337–1347.
    1. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3) J Cyst Fibros. 2007;6(6):403–410.
    1. Sabetta J.R., DePetrillo P., Cipriani R.J., Smardin J., Burns L.A., Landry M.L. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS ONE. 2010;5(6) e11088.
    1. Manaseki-Holland S., Qader G., Isaq Masher M., Bruce J., Zulf Mughal M., Chandramohan D. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010;15(10):1148–1155.
    1. Urashima M., Segawa T., Okazaki M., Kurihara M., Wada Y., Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza a in schoolchildren. Am J Clin Nutr. 2010;91(5):1255–1260.
    1. Amrein K., Litonjua A.A., Moromizato T., Quraishi S.A., Gibbons F.K., Pieber T.R. Increases in pre-hospitalization serum 25(OH)D concentrations are associated with improved 30-day mortality after hospital admission: a cohort study. Clin Nutr. 2016;35(2):514–521.
    1. Amrein K., Sourij H., Wagner G., Holl A., Pieber T.R., Smolle K.H. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. Crit Care. 2011;15(2):R104.
    1. Leaf D.E., Croy H.E., Abrahams S.J., Raed A., Waikar S.S. Cathelicidin antimicrobial protein, vitamin D, and risk of death in critically ill patients. Crit Care. 2015;19(1):80.
    1. Leaf D.E., Raed A., Donnino M.W., Ginde A.A., Waikar S.S. Randomized controlled trial of calcitriol in severe sepsis. Am J Respir Crit Care Med. 2014;190(5):533–541.
    1. Han J.E., Ziegler T.R. Vitamin D supplementation in sepsis and critical illness: where are we now? Am J Respir Crit Care Med. 2014;190(5):483–485.
    1. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.
    1. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonca A., Bruining H. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22(7):707–710.
    1. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332.
    1. Amrein K., Schnedl C., Holl A., Riedl R., Christopher K.B., Pachler C. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014;312(15):1520–1530.
    1. Quraishi S.A., De Pascale G., Needleman J.S., Nakazawa H., Kaneki M., Bajwa E.K. Effect of cholecalciferol supplementation on Vitamin D status and cathelicidin levels in sepsis: a randomized, placebo-controlled trial. Crit Care Med. 2015;43(9):1928–1937.
    1. Ginde A.A., Mansbach J.M., Camargo C.A., Jr Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the third national health and nutrition examination survey. Arch Intern Med. 2009;169(4):384–390.
    1. Laaksi I., Ruohola J.P., Tuohimaa P., Auvinen A., Haataja R., Pihlajamaki H. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007;86(3):714–717.
    1. Finklea J.D., Grossmann R.E., Tangpricha V. Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studies. Adv Nutr. 2011;2(3):244–253.
    1. Janssens W., Lehouck A., Carremans C., Bouillon R., Mathieu C., Decramer M. Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med. 2009;179(8):630–636.
    1. Ferrari M., Schenk K., Papadopoulou C., Ferrari P., Dalle Carbonare L., Bertoldo F. Serum 25-hydroxy vitamin D and exercise capacity in COPD. Thorax. 2011;66(6):544–545.
    1. Hagaman J.T., Panos R.J., McCormack F.X., Thakar C.V., Wikenheiser-Brokamp K.A., Shipley R.T. Vitamin D deficiency and reduced lung function in connective tissue-associated interstitial lung diseases. Chest. 2011;139(2):353–360.
    1. Sutherland E.R., Goleva E., Jackson L.P., Stevens A.D., Leung D.Y. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med. 2010;181(7):699–704.
    1. Grossmann R.E., Zughaier S.M., Kumari M., Seydafkan S., Lyles R.H., Liu S. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: a randomized, controlled trial. Dermatoendocrinol. 2012;4(2):191–197.
    1. Nair P., Venkatesh B., Lee P., Kerr S., Hoechter D.J., Dimeski G. A randomized study of a single dose of intramuscular cholecalciferol in critically Ill adults. Crit Care Med. 2015;43(11):2313–2320.
    1. McCarthy E.K., Kiely M. Vitamin D and muscle strength throughout the life course: a review of epidemiological and intervention studies. J Hum Nutr Diet. 2015;28(6):636–645.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir